Stifel analysts increased their price target for Disc Medicine (NASDAQ:IRON) shares to $94.00, up from the previous $90.00. Currently trading at $57.07 with a market capitalization of $1.7 billion, ...

By the third day, the dizziness had made it impossible for me to walk unaided. I couldn’t sit upright without toppling over.

Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the company will encore data from the BEACON Phase 1/2 ...

Fourteen-day continuous glucose monitoring (CGM) traces added to Diabetes Control and Complications Trial (DCCT) data can ...

Novo Nordisk is opening a new front in its fight against sickle cell disease, inking a deal with IMMvention Therapeutix to co ...

IMMvention Therapeutix, Inc ., an early-stage biotechnology company focused on discovering and developing human therapeutics, today announced a strategic collaboration and license agreement with Novo ...

IMMvention Therapeutix, Inc., a Durham early-stage biotechnology company focused on discovering and developing human ...

Major depressive disorder (MDD) is a debilitating mental health condition characterized by persistent low mood, loss of ...

Beam Therapeutics shows promise in gene therapy for sickle cell disease, but it also has high risks and market expectations.

In his closing thoughts, Dr De Castro provides a final overview of the ASH conference, highlighting updates in PNH treatment.